JNJ-87189401 and JNJ-78278343 for Advanced Prostate Cancer
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Recruiting
Phase 1
Interventional Study
Prostatic Neoplasms
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 355 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
Who this trial is looking for
This trial is looking for men with advanced prostate cancer to test new treatment combinations. Participants will receive a combination of medications and will need to continue certain hormone therapies during the study.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with prostate cancer.
- I have measurable or evaluable cancer.
- I have had an orchiectomy or am on hormone therapy.
- I have an ECOG performance status of 0 or 1.
You may not be able to join if
- I have had an autoimmune disease in the last 12 months.
- I have had a heart attack in the past 6 months.
- I have unstable angina.
- I have significant heart problems or stroke history.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-8718…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is disallowed
* Measurable or evaluable disease …
Contacts